Eli Lilly

Loading... Loading... Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct co...

Eli Lilly (LLY) stock briefly retook its 50-day line in mid-April after its weight-loss drug, tirzepatide, led to fewer nighttime incidents in people with sleep...

Create your free profile or log in to save this article Create your free profile or log in to save this article Despite Eli Lilly’s assurances about an ample...

For Immediate Release Chicago, IL – April 18, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research a...

Dive Brief: Metsera, a richly funded biotechnology startup, launched Thursday with a portfolio of weight loss drugs the company claims could eventually compete...

For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side). Some good news from a...

Wednesday, April 17, 2024 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports...

Apr 17, 2024|04:31 PM ET|ALISSA CORAM, KEN SHREVE The 10-year Treasury yield dropped 7 basis points to around 4.59%, but sellers still hit growth stocks hard....

Eli Lilly's weight loss-related drug Zepbound could potentially be used to reduce the severity of sleep apnea in adults with obesity, according to a recent stud...

Eli Lilly 's weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world's most valuable...